Orticumab
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01258907)
Timeline
Indications
Mechanism of action
- LDL receptorANTAGONIST
LDLR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109532 ↗
Also known as
- mldl1278a
- rg-7418
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01486823 | Phase 1 | Nov 1, 2011 | BioInvent International AB, Genentech, IQVIA |
| NCT01258907 | Phase 2 | Mar 1, 2010 | BioInvent International AB, Genentech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioInvent International AB | For profit | 2 | 1 | 2 | 2010 |
| Genentech | For profit | 2 | 1 | 2 | 2010 |
| IQVIA | For profit | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1